1 / 27

MACROLIDES in LOWER RESPIRATORY TRACT INFECTIONS

MACROLIDES in LOWER RESPIRATORY TRACT INFECTIONS. Dr. Alpay AZAP Ankara University Medical School Infectious Diseases and Clin Micr Dept. Transparency decleration : I have no conflicts of interest. MACROLIDES. Erythromycin Roxythromycin C larithromycin Azithromycin Dyrithromycin

xue
Télécharger la présentation

MACROLIDES in LOWER RESPIRATORY TRACT INFECTIONS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MACROLIDES in LOWER RESPIRATORY TRACT INFECTIONS Dr. Alpay AZAP Ankara UniversityMedicalSchool InfectiousDiseasesandClinMicrDept

  2. Transparencydecleration: I havenoconflicts of interest

  3. MACROLIDES Erythromycin Roxythromycin Clarithromycin Azithromycin Dyrithromycin Telithromycin* Gram pozitivebacteria Gram negativebacteria Atypicalagents Mycobacteriumspp. Borreliaburgdorferi Babesiamicroti RespiratoryPathogens: Streptococcuspneumoniae Haemophilusinfluenzae Moraxellacatarrhalis Legionellaspp. Mycoplasmapneumoniae Chlamydiapneumophila

  4. TurkishThoracicSociety: Group IA: Amoxicillinor MACROLIDE Group IB: “2nd/3rd gen SF or AMC” ± MACROLIDE or Doxycycline Group II: “3rd gen SF or BLBLI + MACROLIDE” or “Fluoroquinolonealone” Grup IIIA: “3rd gen SF or BLBLI” + “MACROLIDE orquinolone” Grup IIIB: Anti-pseudomonal BL + ciprofloxacin/AGA + MACROLIDE MACROLİDES: ErythromycinAzithromycin ClarithromycinRoxythromycin Dyrithromycin J TurkishThoracicSociety 2009;10(s9):3-16

  5. EuropeanRespiratorySociety: Outpatient: Amoxicillinortetracyclineor MACROLIDE Inpatient: “Aminopenicillin ± MACROLIDE” or “BLI-aminopenicillin ± MACROLIDE” or “Penicillin G ± MACROLIDE” or “CTX/CRO ± MACROLIDE” or levofloxacin/moxifloxacin ICU Patient: 3rd gen SF + MACROLIDE OR levofloxacin/moxifloxacin ± 3rd gen SF Anti-pseudomonal BL + “Ciprofloxacinor AGA + MACROLIDE” ClinMicrobiol Infect 2011; 17 (Suppl. 6): 1–24

  6. IDSA/ATS Guideline: Outpatient: Healthywith no risk for PRSP : MACROLIDEσorDoxycycline* Underlyingdis, previousABx: Fluoroquinoloneor Beta-lactam + “MACROLIDEσorDoxycycline” σ : If PRSP incidencelowerthan %25! Inpatient: Fluoroquinoloneor Beta-lactam + “MACROLIDE orDoxycycline” Clinical Infectious Diseases 2007; 44:S27–72

  7. IDSA/ATS Guideline: ICU Patient: CRO/CTX/BLBLI + “Azithromycin * orFluoroquinolone ” ICU Patient (Pseudomonas): Anti-pseudomonal BL + “ciprofloxacinorlevofloxacin” Anti-pseudomonal BL + AGA + Azithromycin Anti-pseudomonal BL + AGA + respiratoryquinolone Clinical Infectious Diseases 2007; 44:S27–72

  8. Macrolideresistance in S. pneumoniae : 4-70% “Prospective ResistantOrganism Tracking and Epidemiology for the KetolideTelithromycin” (PROTEKT)Study: 25 country 69 centers 3362 S. pneumoniaeisolates Macrolideresistance: France: %57.6 Italy: %42.9 Türkiye: %15.6 Sweden: %4.7 J AntimicrobChemoth 2002; 50 (Suppl S1): 25-37.

  9. Türkiye • Fourprovinces, 5 centers • 1995-2000 • 283 pneumococcusisolates • Macrolideresistance: 2.3% • Int J Antimicrob Ag 2002; 19: 207-11

  10. 1999-2005 300 S. pneumoniaeisolatesnvasiveinfections Anti-microbialsensitivitytestingby E-test mef(A) anderm(B) genotypeswereidentifiedby PCR

  11. erm(B) genotype: 58,8% mef(A) genotype: 38,2% erm(B) + mef(A): 3% Turk J Med Sci2012; 42 (1): 137-144

  12. e-BASKETT-II Study: 2002-2003 18 center 260 respiratoryisolates Macrolideresistance: 17.3% Tetracyclineresistance: 21.5% erm(B) genotype: 77,8% mef(A) genotype: 17,8 % erm(B) + mef(A):2,2 % Mikrobiyol Bul. 2007 Jan;41(1):1-9.

  13. Seven centersfrom 5 provinces 301 isolatesfromcommunityacquiredinfections Childandadultpatients Journal of Antimicrobial Chemotherapy (2007) 60, 587–593

  14. Seven centersfrom 5 provinces 380 isolatesfromcommunityacquiredinfections Childandadultpatients Journal of Antimicrobial Chemotherapy (2007) 60, 587–593

  15. Do weneedmacrolides in combination? Clinical Infectious Diseases 2008; 47:S232–6

  16. BMJ 2005; 330:456–60.

  17. Beta-lactam + Macrolidecombination is not synergistic Antagonismwasobserved in animalstudies Selectionbias: Atypicalpneumoniae has a mildcourseandseen in youngerpts Patientswhorequire ICU alsoreceivemacrolides (legionella ?) Theincidence of atypicalagentsshowsvariation. Trialscomparingquinoloneswithmacrolidesdon’tinclude severe pts Journal of Antimicrobial Chemotherapy (2003) 52, 555–563

  18. BL + Macrolide vs Fluoroquinolone: PSI V pts 14 daymortality; 8.2% vs 26.8% (p=0.02) 30 daymortality: 18.4% vs 36.6% (p=0.05) PSI II-IV pts 14 day, 30 daymortalityand LOS were not different Length of stay in allpts 6 days vs 5 days (p=0.01) ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2007, p. 3977–3982

  19. 9 countiresfromEuropa 27 ICUs, 218 entubated severe CAP pts 43 (19.7%) ptsmonotherapy 175 (80.3%) ptsdualtherapy BL + Macrolide vs BL + Quinolone: severe CAP pts: HR: 0.48 (p=0.04) severe sepsis/septicshock: HR: 0.44 (p=0.03) Intensive Care Med (2010) 36:612–620

  20. Intensive Care Med (2010) 36:612–620

  21. Intensive Care Med (2010) 36:612–620

  22. Macrolide!WhichOne ? TurkishThoracicSociety: Macrolides: Erythromycin Roxythromycin Clarithromycin Azithromycin Dyrithromycin Türk Toraks Dergisi 2009;10(s9):3-16 • IDSA/ATS : • Azithromycinfor ICU pts • Clinical Infectious Diseases 2007; 44:S27–72

  23. toconclude… Macrolides can be used as monotherapyagentfor CAP in Türkiye Macrolidesmay be superiorthanquinoloneswhenused in combinationwith BL agents Thedecision of whichmacrolideshould be useddepends on patientsclincalsituation.

  24. Thankyou….

More Related